Literature DB >> 7707331

Distribution of serovariants of group B streptococci in isolates from England and Norway.

A I Kvam1, A Efstratiou, L Bevanger, B D Cookson, I F Marticorena, R C George, J A Maeland.   

Abstract

The distribution of capsular polysaccharide antigen (CHO) types, surface-exposed c proteins alpha (c alpha) and beta (c beta) and an R-protein antigen was examined in 334 group B streptococci (GBS) isolates from three groups of patients hospitalised in England and Wales or Norway. The isolates were from 108 carriers, 67 cases of neonatal infection and 154 cases of adult infection. Each group contained all CHO types (Ia, Ib, II, III, IV, V and NT); type III strains predominated except in the adult infected group. Strains within each CHO type could be further subdivided by the protein markers into five subtypes by a combined typing system. The proportion of type Ib and type III strains in the neonatal infection cases and of type Ib strains in the adult infection cases significantly outnumbered isolates of these serotypes among the carrier strains. Twenty-nine different serovariants were identified; 24, 13 and 23 serovariants among the carrier, neonatal infection and adult infection isolates, respectively. Certain CHO antigen-protein associations were identified, notably those between Ia/c alpha, Ib/c alpha beta and III/R. The proportion of invasive isolates that expressed protein was not higher than in the carrier isolates. All CHO-type Ib isolates contained a c protein, but 7% of the Ib isolates did not contain any of these proteins. These findings indicate that this combined typing approach may be useful in examining epidemiological problems associated with GBS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707331     DOI: 10.1099/00222615-42-4-246

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  9 in total

1.  Immunological markers of the R4 protein of Streptococcus agalactiae.

Authors:  Johan A Maeland; Lars Bevanger; Randi Valsoe Lyng
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

2.  Molecular profiles of group B streptococcal surface protein antigen genes: relationship to molecular serotypes.

Authors:  Fanrong Kong; Sonia Gowan; Diana Martin; Gregory James; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

3.  bca, beta gene, and gene product divergency in reference and prototype strains of streptococcus agalactiae.

Authors:  J A Maeland; L Bevanger; G Iversen; R V Lyng
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

4.  Antibodies against Streptococcus agalactiae proteins c(alpha) and R4 in sera from pregnant women from Norway and Zimbabwe.

Authors:  S R Moyo; J A Maeland; J Mudzori
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

5.  Genotyping of the capsule gene cluster (cps) in nontypeable group B streptococci reveals two major cps allelic variants of serotypes III and VII.

Authors:  M Sellin; C Olofsson; S Håkansson; M Norgren
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Reverse line blot assay for direct identification of seven Streptococcus agalactiae major surface protein antigen genes.

Authors:  Zuotao Zhao; Fanrong Kong; Gwendolyn L Gilbert
Journal:  Clin Vaccine Immunol       Date:  2006-01

7.  A serotype VIII strain among colonizing group B streptococcal isolates in Boston, Massachusetts.

Authors:  L J Paoletti; J Bradford; L C Paoletti
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

8.  Antigenic determinants of alpha-like proteins of Streptococcus agalactiae.

Authors:  Johan A Maeland; Lars Bevanger; Randi Valsoe Lyng
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

9.  Distribution of novel and previously investigated virulence genes in colonizing and invasive isolates of Streptococcus agalactiae.

Authors:  T C Smith; S A Roehl; P Pillai; S Li; C F Marrs; B Foxman
Journal:  Epidemiol Infect       Date:  2006-12-07       Impact factor: 2.451

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.